Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Fragile X Syndrome-Pipeline Review, H1 2015

Fragile X Syndrome-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Fragile X Syndrome-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Fragile X Syndrome-Pipeline Review, H1 2015', provides an overview of the Fragile X Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fragile X Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fragile X Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Fragile X Syndrome

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Fragile X Syndrome and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Fragile X Syndrome pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Fragile X Syndrome Overview 8

Therapeutics Development 9

Pipeline Products for Fragile X Syndrome-Overview 9

Pipeline Products for Fragile X Syndrome-Comparative Analysis 10

Fragile X Syndrome-Therapeutics under Development by Companies 11

Fragile X Syndrome-Therapeutics under Investigation by Universities/Institutes 12

Fragile X Syndrome-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Fragile X Syndrome-Products under Development by Companies 16

Fragile X Syndrome-Products under Investigation by Universities/Institutes 17

Fragile X Syndrome-Companies Involved in Therapeutics Development 18

Aelis Farma S.A.S. 18

Alcobra Ltd 19

Confluence Pharmaceuticals LLC 20

Cortex Pharmaceuticals, Inc. 21

Eli Lilly and Company 22

F. Hoffmann-La Roche Ltd. 23

Marinus Pharmaceuticals, Inc. 24

MI.TO. Technology S.r.L. 25

Neuren Pharmaceuticals Limited 26

Selvita SA 27

Fragile X Syndrome-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

acamprosate calcium-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

basimglurant-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Bryostatin-1-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

cercosporamide-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

CX-929-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Drugs to Inhibit mGluR5 for Fragile X Syndrome-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

flindokalner-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

gaboxadol-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

ganaxolone-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Metadoxine ER-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

minocycline-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

NNZ-2591-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

SEL-203-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecule for FXTAS-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Small Molecule to Activate Epsilon PKC for Fragile X Syndrome-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecules to Agonize 5-HT7 for Fragile X Syndrome-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

SRT-278-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

trofinetide-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Fragile X Syndrome-Recent Pipeline Updates 64

Fragile X Syndrome-Dormant Projects 78

Fragile X Syndrome-Discontinued Products 80

Fragile X Syndrome-Product Development Milestones 81

Featured News & Press Releases 81

Apr 16, 2015: Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies 81

Apr 09, 2015: Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome 81

Mar 02, 2015: Neuren receives FDA response to request for Breakthrough Therapy 82

Feb 16, 2015: Neuren receives Orphan Drug designation from FDA for trofinetide in Rett syndrome 83

Jan 28, 2015: Neuren Announces Trofinetide as Proposed International Nonproprietary Name for NNZ-2566 83

Jan 27, 2015: Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day 84

Dec 30, 2014: Neuren submits Orphan Drug and Breakthrough Therapy applications to the FDA 84

Nov 13, 2014: Marinus Pharmaceuticals Provides Update On Ganaxolone 84

Oct 23, 2014: Alcobra Announces Presentation of New Data From Phase III Adult ADHD Study at AACAP Annual Meeting 85

Sep 02, 2014: Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Adolescents With ADHD 87

Appendix 88

Methodology 88

Coverage 88

Secondary Research 88

Primary Research 88

Expert Panel Validation 88

Contact Us 88

Disclaimer 89

List of Tables

Number of Products under Development for Fragile X Syndrome, H1 2015 9

Number of Products under Development for Fragile X Syndrome-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Comparative Analysis by Unknown Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Fragile X Syndrome-Pipeline by Aelis Farma S.A.S., H1 2015 18

Fragile X Syndrome-Pipeline by Alcobra Ltd, H1 2015 19

Fragile X Syndrome-Pipeline by Confluence Pharmaceuticals LLC, H1 2015 20

Fragile X Syndrome-Pipeline by Cortex Pharmaceuticals, Inc., H1 2015 21

Fragile X Syndrome-Pipeline by Eli Lilly and Company, H1 2015 22

Fragile X Syndrome-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 23

Fragile X Syndrome-Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 24

Fragile X Syndrome-Pipeline by MI.TO. Technology S.r.L., H1 2015 25

Fragile X Syndrome-Pipeline by Neuren Pharmaceuticals Limited, H1 2015 26

Fragile X Syndrome-Pipeline by Selvita SA, H1 2015 27

Assessment by Monotherapy Products, H1 2015 28

Number of Products by Stage and Target, H1 2015 30

Number of Products by Stage and Mechanism of Action, H1 2015 32

Number of Products by Stage and Route of Administration, H1 2015 34

Number of Products by Stage and Molecule Type, H1 2015 36

Fragile X Syndrome Therapeutics-Recent Pipeline Updates, H1 2015 64

Fragile X Syndrome-Dormant Projects, H1 2015 78

Fragile X Syndrome-Dormant Projects (Contd..1), H1 2015 79

Fragile X Syndrome-Discontinued Products, H1 2015 80

List of Figures

Number of Products under Development for Fragile X Syndrome, H1 2015 9

Number of Products under Development for Fragile X Syndrome-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 28

Number of Products by Top 10 Targets, H1 2015 29

Number of Products by Stage and Top 10 Targets, H1 2015 29

Number of Products by Top 10 Mechanism of Actions, H1 2015 31

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Top 10 Routes of Administration, H1 2015 33

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 34

Number of Products by Top 10 Molecule Types, H1 2015 35

Number of Products by Stage and Top 10 Molecule Types, H1 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aelis Farma S.A.S.

Alcobra Ltd

Confluence Pharmaceuticals LLC

Cortex Pharmaceuticals, Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Marinus Pharmaceuticals, Inc.

MI.TO. Technology S.r.L.

Neuren Pharmaceuticals Limited

Selvita SA

Fragile X Syndrome Therapeutic Products under Development, Key Players in Fragile X Syndrome Therapeutics, Fragile X Syndrome Pipeline Overview, Fragile X Syndrome Pipeline, Fragile X Syndrome Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com